Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.

Julio RosenstockJohn B BuseRehan AzeemPrakash PrabhakarLise KjemsHolly HuangMichelle A Baron

Published in: Diabetes care (2017)

ITCA 650 significantly reduced HbA1c and weight compared with placebo and was well tolerated in patients with uncontrolled type 2 diabetes on oral antidiabetes medications.

Keyphrases

type diabetes
glycemic control
phase iii
cardiovascular disease
insulin resistance
body mass index
clinical trial
study protocol
physical activity
weight loss
weight gain
emergency department
body weight